Shwachman-Diamond syndrome (SDS) is a rare multi-organ recessive disease mainly characterised by pancreatic insufficiency, skeletal defects, short stature and bone marrow failure (BMF). As in many other BMF syndromes, SDS patients are predisposed to develop a number of haematopoietic malignancies, particularly myelodysplastic syndrome and acute myeloid leukaemia. However, the mechanism of cancer predisposition in SDS patients is only partially understood. In light of the emerging role of mesenchymal stromal cells (MSCs) in the regulation of bone marrow homeostasis, we assessed the ability of MSCs derived from SDS patients (SDSMSCs) to recreate a functional bone marrow niche, taking advantage of a murine heterotopic MSC transplant model. We show that the ability of semi-cartilaginous pellets (SCPs) derived from SDS-MSCs to generate complete heterotopic ossicles in vivo is severely impaired in comparison with HD-MSC-derived SCPs. Specifically, after in vitro angiogenic stimuli, SDSMSCs showed a defective ability to form correct networks, capillary tubes and vessels and displayed a marked decrease in VEGFA expression. Altogether, these findings unveil a novel mechanism of SDS-mediated haematopoietic dysfunction based on hampered ability of SDS-MSCs to support angiogenesis. Overall, MSCs could represent a new appealing therapeutic target to treat dysfunctional haematopoiesis in paediatric SDS patients.
Introduction
Shwachman-Diamond syndrome (SDS, Online Mendelian Inheritance in Man reference 260400) is a rare multi-organ recessive disease characterised by bone marrow (BM) dysfunctions, exocrine pancreatic insufficiency and failure to thrive. Diagnosis is based on both clinical phenotype and genetic analysis of the SBDS gene, which encodes the SBDS protein and is mutated in 90% of SDS patients (Boocock et al, 2003) . Frequently defined as ribosomopathy, SDS is thought to be the third most common inherited bone marrow failure (BMF) after Fanconi anaemia and DiamondBlackfan anaemia (Dror, 2005) . Typical features of SDS patients are neutropenia and a generalized condition of cytopenia accompanied by the reduced capability of neutrophils to respond to chemotactic stimuli and decreased
CD34
+ clonogenic potential (Dror & Freedman, 1999) . As for other BMF syndromes, SDS patients are at higher risk of developing myelodysplastic syndrome (MDS) and other haematopoietic malignancies, particularly acute myeloid leukaemia (AML). The cellular and molecular pathways underlying haematopoietic neoplastic predisposition in SDS patients are only partially understood. The evidence of a central role played by mesenchymal stromal cells (MSCs) in haematological dysfunctions came from studies by Raaijmakers et al (2010) , who were able to recapitulate key features of human MDS by deleting the Dicer1 gene in murine mesenchymal osteoprogenitors in vivo. Our group succeeded for the first time in isolating and characterising MSCs derived from SDS patients (SDS-MSCs) by comparing them to MSCs obtained from healthy donors (HD-MSCs) (Andre et al, 2012) . We found that SDS-MSCs displayed morphology, growth kinetics and expression of surface markers undistinguishable from those of HD-MSCs. SDS-MSCs were also able to support viability and stemness of CD34 + cells and showed a normal karyotype (Andre et al, 2012) . Nevertheless, several genes involved in haematopoietic cell development, lymphopoiesis and neoplastic progression were differently expressed between SDS-MSCs vs HD-MSCs (unpublished data). Based on these preliminary findings, we hypothesized that these different gene expression patterns may affect the functional properties of SDS-MSCs (unpublished observations). Here, using both in vitro and in vivo models, we expand the characterisation of SDS-MSCs and show that SDS-derived MSCs display a marked impairment in their angiogenic potential, resulting in the formation of dysfunctional bone marrow niches.
Methods

Patients
Mesenchymal stromal cells were obtained from fresh or frozen BM samples derived from diagnostic specimens collected from 29 out of 124 SDS patients enrolled in the SDS Italian registry. Samples were obtained after informed consent released by the legal guardians or, whenever eligible, by the patients themselves. Seventeen out of 29 were newly diagnosed SDS patients. SDS diagnosis was based on clinical evaluation and SBDS gene mutations at time of diagnosis. The median age at enrolment was 9 years (range 1-38). Table I shows the main genetic characteristics of all SDS patients enrolled in this study. MSCs from 13 age-matched HDs (range 1-48 years) were obtained from collection bags discarded after BM infusion.
Isolation, culture and characterisation of MSCs
Mesenchymal stromal cells were isolated from BM aspirates and cultured as previously described (Andre et al, 2012) . Briefly, mononuclear cells were isolated using Ficoll-Paque 
Chondrogenic differentiation
MSCs derived from HDs or SDS patients at p3 were grown for 21 days in 15 ml polypropylene conical tubes at a density of 300,000 cells/tube in chondrogenic differentiation medium [Dulbecco's modified Eagle medium-High glucose (Euroclone) supplemented with ITS TM premix (5 lg/ml insulin, 5 lg/ml transferrin, 5 ng/ml selenious acid, BD), 1 mM pyruvate (Sigma-Aldrich, St. Louis, MO, USA), 50 lg/ml 2-phosphate-ascorbic acid (Sigma-Aldrich), 100 nmol/l dexamethasone (Sigma-Aldrich), and 10 ng/ml TGFb-1 (R&D systems, Minneapolis, MN, USA)]. On day 21 of in vitro culture, cartilaginous pellets were washed twice with PBS, fixed with a solution of PBS with 4% formaldehyde (SigmaAldrich), and accumulation of cartilage matrix was evaluated by haematoxylin and eosin (H&E) staining of paraffinembedded sections and images acquired by an Olympus BX51 microscope (Olympus, Tokyo, Japan).
In vivo transplantation and ossicle formation Calco, MI, Italy) as close as possible to blood vessels, as previously described (Serafini et al, 2014 selected according to the Software Probe Finder (Roche Diagnostics) and listed in Table II . For VEGFA, the SybrGreen (Invitrogen) assay was performed as previously described (Niu et al, 2012) . We used B-glucuronidase (GUSB) as reference gene and for target gene normalization. Three independent replicates were performed for each gene.
Angiogenesis assay
40 000 MSCs at p5 or p6 were seeded in duplicate in 24-well plates, pre-coated with 250 ll of Matrigel (Corning, New York USA). Cells were resuspended in Vascular Cell Basal Medium (PCS-100-030; American Type Culture Collection, Manassas, VA, USA) supplemented with 5% FBS and different pro-angiogenic factors, following the manufacturer's instructions. After a 3-h incubation at 37°C, capillary tube formation was assessed with a phase-contrast microscope. Three photographs for each well were acquired by means of a phase-contrast microscope (Zeiss Axiovert40C; Zeiss, Obercocken, Germany) and analysed using the ImageJ Angiogenesis Analyser (http://rsb.info.nih.gov/ij). To isolate MSCs at the end of the experimental time, Matrigel from each well was digested with 1 ml of Hank's Balanced Salt Solution (Gibco/Invitrogen, Thermo Fisher Scientific) containing 10 units/ml dispase (Roche) for 1 h at 37°C. After incubation, cells were washed twice with ice-cold PBS and centrifuged at 1,800 rpm for 5 min. The RNA was extracted as previously described and qPCR assays were performed.
Statistical analysis
Results were presented as mean AE standard deviation (SD) and analysed by Student's t test. P-values ≤ 0Á05 were considered statistically significant.
Results
SDS-MSCs can form in vitro semi-cartilaginous pellets
First, newly collected SDS-MSCs were characterised for their phenotype and ability to differentiate into adipocytes or osteocytes. After confirming their resemblance to HD-MSCs in terms of surface marker expression and differentiation capacity, as previously shown by Andre et al (2012) (Figure S1 ), we assessed their ability to differentiate into chondrocytes and create semi-cartilaginous pellets (SCPs). No differences were found in terms of chondrogenic matrix deposition between SDS-and HD-MSCs. Specifically, the extent of chondrogenic differentiation observed in 19 out of 29 SDS patients (65Á5%) was virtually the same as that recorded in 9 out of 13 healthy donors (69%) (Fig 1A) . Figure 1B shows representative H&E staining of HD-and SDS-MSC SCPs. Thus, the ability of MSCs derived from SDS patients to differentiate into functional chondrocytes appears to be unaltered.
SDS-MSCs are not able to recreate an in vivo BM niche
We next assessed the ability of SDS-MSCs to support haematopoiesis taking advantage of an in vivo model able to recapitulate the characteristics of BM microenvironments (Serafini et al, 2014) . To this end, we transplanted HD-or SDS-SCPs, which showed a correct grade of in vitro chondrogenic differentiation when determined by histological analysis, subcutaneously in immunocompromised mice. Eight weeks after transplant, ossicles were harvested and analysed to assess BM establishment. Remarkably, we could only observe bone remodelling and marrow establishment in HD-SCP transplants, whereas we could not find any histological evidence of complete BM niche formation in SDS-SCP specimens (Fig 2A) . In particular, macroscopic evaluation of ossicles derived from seven different HD-SCPs harvested after 8 weeks of transplantation displayed a red colour and a hard consistency, indicating the bone formation and haematopoietic cell colonization. Subsequent microscopic analysis of H&E stained HD-SCP samples confirmed that a complete heterotopic BM niche formation had taken place. The Fig 2B, left panel) . By contrast, we implanted a total number of 150 SDS-SCPs obtained from 19 different patients, but we were only able to harvest 24 pellets (16%), none of which displayed vascularization or BM niche formation (Fig 2A) . In particular, these SDS-SCPs specimens mainly consisted of undifferentiated mesengetic tissue, presumably due to a block of differentiation at the chondrogenic phase. In detail, inflammatory elements, such as infiltrating macrophages (Fig 2B, panel 1) were found in two SCPs, while mesengetic undifferentiated tissue was detected in six SCPs (Fig 2B,  panel 2 ). The remaining 16 pellets contained chondrogenic tissue (Fig 2B, panels 3 and 4) , three of which were surrounded by fibrotic capsules (Fig 2B, panel 4) . The remaining 126 SDS-SCPs (84%) had been probably resorbed during the in vivo period as we were not able to find and harvest any of them.
Differences between HD-and SDS-SCPs are evident after 4 weeks of transplantation
To further characterise the kinetics of ossicle formation in SCP-transplanted mice, we performed histological analysis on ossicle specimens obtained from one HD and three SDS patients [Unique patient number (UPN) 19, 7 and 13] harvested at 2, 4 and 8 weeks post-transplant. After 2 weeks of transplantation, SDS-derived ossicles did not display any significant difference from HD-derived ossicles at least in terms of endochondral cartilaginous matrix composition (Fig 3) . At week 4 post-transplant, resorption of cartilage started to become evident in HD-derived samples, with an initial deposition of osteogenic matrix, whereas in SDS-derived ossicles this process appeared to be far less evident, if not totally absent (Fig 3) . At week 8 post-transplant, we could only detect complete BM niche formation in HD-but not SDS-derived ossicles. In particular, we failed to collect ossicles from one SDS patient, whereas in the two other cases the ossicles showed neither vascularization nor BM niche formation (Fig 3) . In good agreement with our previous results, in these two specimens, we could only find chondrogenic and some osteogenic tissue without any evidence of progression to ossicle formation. Next, we sought to determine expression levels of a number of genes associated with hypoxia, angiogenesis, invasion, inflammation and other processes linked to ossicle formation. For this purpose, mRNA samples obtained from 4-week transplanted pellets from SDS patients or HDs were subject to qPCR. All tested genes were not differentially expressed in our two mRNA subsets ( Figure S2 ). Of note, we failed to detect above-background expression levels of genes that encode inflammatory cytokines, such as IL1B, IL6, TNF and IFNG ( Figure S2 ).
SDS-MSCs display impaired angiogenesis in vitro
Due to the fact that harvested ossicles derived from SDS patients displayed absence of vascularization, we asked whether SDS-MSCs could support angiogenesis in vivo, a crucial step for complete BM establishment. To answer this question, we first assessed the extent of capillary tube formation in HD-vs SDS-MSCs using an in vitro angiogenesis assay. Remarkably, we found that the ability of SDS-MSCs to form correct networks and reorganize themselves to form capillary tubes and vessels was severely impaired in comparison with that of HD-MSCs (Fig 4A) . Specifically, SDS-MSCs formed disorganized cell aggregates that were readily visible in the middle of the culture well, whereas HD-MSCs gave rise to well-defined structures that were evenly well-spread across the culture. Moreover, the number of junctions, meshes and segments was markedly reduced in SDS-MSCs vs. HD-MSCs (Fig 4B) . Specifically, junctions and master junctions formed by SDS-MSCs had mean values of 145Á4 AE 70Á1 and 117Á9 AE 64Á6, respectively, which were significantly lower than those recorded in HD-MSC specimens (i.e. 226Á2 AE 57Á8 and 197Á7 AE 57Á7, respectively; P ≤ 0Á05). Also, the number of segments and master segments was significantly diminished in SDS-MSCs compared to HD-MSCs (i.e. 199Á9 AE 101Á5 vs. 321Á6 AE 86Á4, and 183Á2 AE 97Á5 vs. 304Á7 AE 89Á0, respectively; P ≤ 0Á05). The branching interval and the number of meshes were the parameters most strongly reduced in SDSvs HD-MSCs (351,167Á7 AE 149,388Á2 vs. 533,840Á5 AE 76,407Á9; P = 0Á02; and 61Á4 AE 32Á7 vs. 104Á1 AE 31Á3; P = 0Á04, respectively), while the number of nodes was only slightly decreased in SDS-MSCs compared to HD-MSCs [500Á1 AE 242Á4 vs 782Á0 AE 201Á4, respectively; P = 0Á053).
To better characterise the SDS-MSCs phenotype, a number of genes involved in the angiogenic process and related to endothelial cells were analysed by PCR in unstimulated MSCs or after 3 h of angiogenic stimulation with matrigel and other angiogenic factors contained in the vascular medium. SDS-MSCs expressed lower basal levels of ACTA2, a gene involved in motility and contraction, in comparison with those seen in HD-MSCs. However, in response to angiogenic stimulation, ACTA2 was slightly, but not significantly, upregulated by 1Á74-fold in SDS-MSCs, and levels remained basically unchanged in HD-MSCs. Interestingly, both CSPG4 (also termed NG2) and PECAM1, genes known to regulate pericyte and endothelial cell functions as well as angiogenesis, were significantly upregulated over baseline in HD-MSCs (12-and 24-fold induction, respectively) but not in SDS-MSCs, which showed a trend of increase not statistically significant after angiogenic stimulation (Fig 5) . We next turned our attention to VEGFA, a master regulator of angiogenesis. In unstimulated conditions, VEGFA expression levels in HD-and SDS-MSCs were virtually undistinguishable. However, after angiogenic stimulation, VEGFA expression Gene expression on mesenchymal stromal cells after angiogenesis assay. The expression of ACTA2, CSPG4, PECAM1 and VEGFA was evaluated using a quantitative real time polymerase chain reaction under both basal (-) and angiogenic (Matrigel) culture conditions. n = 5/6 per group. *P ≤ 0Á05; * ** P < 0Á001. Statistical analysis was performed using Student's t test. HD: healthy donors; SDS: Shwachman-Diamond syndrome patients. with pro-angiogenic factors and medium. After 3 h, capillary tube formation was assessed with a phase-contrast microscope. Well organized networks were formed by MSCs for healthy donors (HD-MSCs) compared to aggregates and drastically diminished vessel formation in ShwachmanDiamond syndrome (SDS) samples. (B) Analyses of different parameters related to angiogenesis and representative photographs of each group (HD and SDS) acquired by phase-contrast microscopy. Data are presented as mean values AE SD (n = 6 per group) of two independent experiments. *P < 0Á05. Statistical analysis was performed using Student's t test. levels slightly increased only in HD-MSCs (2Á8-fold) but not in SDS-MSCs where levels fell well below baseline (P = 0Á017 vs. basal condition) (Fig 5) .
Discussion SDS is a rare autosomal recessive disease, characterised by BM failure, exocrine pancreatic insufficiency and skeletal defects. In addition, the number of BM precursors is further reduced and their viability is impaired, partly due to BM stromal cell dysfunctions. As first demonstrated by Dror and Freedman (1999) , using bone marrow long-term cultures, SDS patients display an impaired ability to support haematopoiesis and defects in cytokine production. In the attempt to provide insights into the mechanism of SDS-mediated haematopoietic dysfunction, we focused our attention on MSCs, whose role in BM niche formation and maintenance, as well as their ability to regulate haematopoiesis, is well established in the context of several BMFs.
To investigate functional defects of SDS-MSCs that could potentially sustain the pathology, we took advantage of an in vivo model that can give rise to a functional BM niche environment (Serafini et al, 2014) . Indeed, following SDS-MSCs characterisation in vitro, we were able to generate SCPs from both HD-and SDS-MSCs specimens (69% vs. 65Á5% respectively). These results are in line with the physiological, donorspecific heterogeneity of in vitro cultured MSCs, which can display tri-, bi-or uni-lineage differentiation capacity.
Even though our in vitro data indicated that both the HD-and SDS-MSCs groups had a similar chondrogenic differentiation potential, we queried whether they retained the ability to form a complex functional BM niche in vivo. With this aim, we subcutaneously transplanted SCPs displaying a good chondrogenic differentiation in immunocompromised mice, thus enabling them recreate a complete BM niche within 8 weeks. Strikingly, we found that only SCPs derived from HDs were able to recreate a functional humanized in vivo niche, completely recapitulating the bone architecture, with bone trabeculae, murine haematopoietic cells and synusoids. This did not occur with SDS-SCPs, which instead generated a very incomplete niche with neither vascularization nor haematopoietic cell invasion, and could only be found in inflammatory elements and fibrotic capsules.
To better define the stage at which the developmental block had occurred, we analysed ossicles at 2, 4 and 8 weeks post-transplant. Whereas at the 2-week time point there were no apparent differences between the two groups, at 4 weeks post-transplant, HD-MSC-derived ossicles had undergone cartilage resorption and initial bone deposition, while SDS-MSC-derived ossicles showed an abnormal differentiating process. Given that the expression of different genes related to matrix invasion, hypoxia and osteo/chondrogenic differentiation was comparable between HD-MSC-and SDS-MSCderived-ossicles at this critical time point (Figure S2 ), we focused our attention on the vascularization process, which was strikingly absent in the SDS samples. It is widely accepted that the replacement of un-mineralised cartilage by stromal tissue, which becomes subsequently colonized by blood vessels, constitutes an essential step for the formation of a functional BM niche. In good agreement with our findings, this process starts at 3 weeks post-transplant (Serafini et al, 2014) . At this time, MSCs critically cooperate to BM niche formation, acquiring adventitial reticular cell characteristics and sustaining murine macrophage and osteoclast invasion to start cartilage resorption. In this regard, recent studies have demonstrated that CD146-expressing MSCs undergo vascular smooth muscle cell lineage commitment (Espagnolle et al, 2014) and dynamically associate with developing sinusoids, generating heterotopic adventitial reticular cells (Sacchetti et al, 2007) . Given that both HD-and SDS-MSCs cultured in vitro ( Figure S1 ) or from 4-week harvested ossicles ( Figure S2 ) display similar levels of CD146 expression, we ruled out a major involvement of this subset in the observed in vivo defects. Consequently, we hypothesised that other defects in the reorganization of SDS-MSCs could be responsible for the failure of BM establishment in our in vivo model.
To investigate the ability of SDS-MSCs to sustain a correct vascularization, we took advantage of an in vitro angiogenesis assays. Remarkably, we observed abnormal reorganization and vascular tube formation in SDS-MSCs compared to HDMSCs. In particular, SDS-MSCs were unable to create a correct and complete angiogenic network, a finding consistent with that observed by others in primary BM biopsy samples (Leung et al, 2006) . Thus, it is tempting to speculate that the reorganization defects of SDS-MSCs observed in vitro could be one of the determinants for the altered marrow biopsy architecture and the absence of vascularization in humanized ossicles harvested from SDS-MSC-transplanted mice.
To further investigate the mechanism of this vascular defect, we analysed the expression of different genes directly or indirectly involved in angiogenesis either before or after the angiogenic assay. Gene expression analysis revealed that HD-MSCs and, to a minor extent, SDS-MSCs are able to upregulate, in response to in vitro angiogenic stimulation, genes related to the mesenchymal-to-endothelial transition, such as CSPG4 and PECAM1. In particular, the proteoglycan encoded by CSPG4 is expressed by stromal cells (Stallcup et al, 2016) and at high levels by vessel-surrounding perycites of mesenchymal origin, which represent fundamental microvascular stabilizers (Trost et al, 2016) . Indeed, surface expression of the platelet endothelial cell adhesion molecule PECAM1 is highly increased in vascular endothelial cells (Newman, 1999) during angiogenic processes, playing a critical role in the organization of the tight junction complex (Ren et al, 2015) and increasing the strength of cell connections (Albelda et al, 1991) . Interestingly, in unstimulated conditions, we observed a significant lower expression of the ACTA2 gene in SDS-MSCs compared to HDMSCs. The protein encoded by this gene, highly expressed by contractile myofibroblasts, is crucially involved in the morphological and cytoskeletal changes underling MSC differentiation into the myogenic lineage Walters et al, 2017) . In line with our data, Rothbaum et al (1982) reported severe cytoskeletal defects in SDS neutrophils, resulting in an abnormal chemotaxis, which could also be found in other cell types including MSCs, thereby compromising MSC-mediated angiogenesis. When we turned out attention to VEGFA, which represents the most important ligand for angiogenic processes, we found comparable VEGFA expression levels in unstimulated HD-and SDS-MSCs. However, after angiogenic stimulation, the upregulation of VEGFA seen in HD-MSCs was completely ablated in SDS-MSCs, where it was well below baseline. Previous data from an in vivo model of traumatic brain injury have shown that transplanted MSCs are able to promote angiogenesis through VEGFA upregulation (Guo et al, 2017) . Furthermore, VEGFA has been shown to be an essential chemoattractant for endothelial cells (Gerber et al, 1999) and osteoclasts invading developing long bones (Engsig et al, 2000) . Thus, it is conceivable that environmental signals, such as hypoxia present in the core of SCPs, could physiologically lead to the activation of angiogenic processes. In this context, a decrease in VEGFA production in stimulated SDSMSCs could account, in part, for the complete lack of vascularization in our in vivo model. Notably, Finch et al (2011) demonstrated that SBDS cooperates with elongation factor-like 1 (EFL1) to directly catalyse eukaryotic translation initiation factor 6 (eIF6) release from pre-60S subunits. Given the role of SBDS in ribosome assembly and maturation, it could be conceivable that protein expression of these genes does not strongly correlate with their mRNA levels. Future studies are clearly needed to further characterise the role of VEGFA in the defective angiogenic process of SDS-MSCs.
In conclusion, we have established for the first time a model of in vivo haematopoietic niche deriving from SDSMSCs. Our findings clearly indicate a defect in ossicle formation in MSCs derived from SDS patients, which could not lead to a complete BM niche establishment. In vitro characterisation of these cells shows impaired vessel formation during angiogenic assay and a defective regulation of some genes crucially involved in capillary tube development. Thus, taken together, our data suggest that functionally altered MSCs could play a pivotal role in vascular, haematological and non-haematological defects typical of SDS.
